GUERBET (GBT.PA) Stock Overview
Europe - EPA:GBT - FR0000032526 - Common Stock
GBT.PA Key Statistics, Chart & Performance
The current stock price of GBT.PA is 15.76 EUR. In the past month the price increased by 21.85%. In the past year, price decreased by -49.89%.
GBT.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| EL.PA | ESSILORLUXOTTICA | 46.37 | 147.54B | ||
| 1EL.MI | ESSILORLUXOTTICA | 46.1 | 146.68B | ||
| ESL.DE | ESSILORLUXOTTICA | 46.08 | 146.63B | ||
| 2U3.DE | ALCON INC | 24.95 | 32.41B | ||
| 1ALC.MI | ALCON INC | 24.62 | 31.98B | ||
| CBHD.DE | COLOPLAST-B | 31.74 | 17.01B | ||
| AFW.DE | ALIGN TECHNOLOGY INC | 14.39 | 8.44B | ||
| GENT.OL | GENTIAN DIAGNOSTICS ASA | 21.12 | 875.86M | ||
| ALCJ.PA | CROSSJECT | N/A | 124.06M | ||
| AFME.PA | AFFLUENT MEDICAL SA | N/A | 56.47M | ||
| SVS.MI | SVAS BIOSANA SPA | 7.24 | 51.52M | ||
| PTP.DE | PENTIXAPHARM HOLDING AG | N/A | 41.07M |
Related stock screener links
About GBT.PA
Company Profile
Guerbet SA engages in the research, development, manufacture, and sale of contrast products for medical imaging. The company is headquartered in Villepinte, Ile-De-France and currently employs 2,905 full-time employees. The company produces medical imaging contrast products for x-ray imaging, magnetic resonance imaging (MRI), ultrasound imaging and for nuclear medicine. The contrast agents are used in the diagnosis of cardio-vascular, inflammatory and neuro-degenerative disorders. The Company’s portfolio of products comprises brands, such as Xenetix, Hexabrix, Optiray, Oxilan, Telebrix, Lipiodol, Dotarem, Endorem, Artirem, Lumirem, and Lipiodol, among others. Guerbet SA is also active in the fine chemicals industry through its Simafex subsidiary. The firm operates through its subsidiaries, including Simafex, Medex, SCI KALB, Guerbet LLC, Guerbet Asie Pacifique and Guerbet GmbH, among others.
Company Info
GUERBET
15 rue des Vanesses, Zone Paris Nord II
Villepinte ILE-DE-FRANCE FR
Employees: 2842
Phone: 33145915000
GUERBET / GBT.PA FAQ
What does GUERBET do?
Guerbet SA engages in the research, development, manufacture, and sale of contrast products for medical imaging. The company is headquartered in Villepinte, Ile-De-France and currently employs 2,905 full-time employees. The company produces medical imaging contrast products for x-ray imaging, magnetic resonance imaging (MRI), ultrasound imaging and for nuclear medicine. The contrast agents are used in the diagnosis of cardio-vascular, inflammatory and neuro-degenerative disorders. The Company’s portfolio of products comprises brands, such as Xenetix, Hexabrix, Optiray, Oxilan, Telebrix, Lipiodol, Dotarem, Endorem, Artirem, Lumirem, and Lipiodol, among others. Guerbet SA is also active in the fine chemicals industry through its Simafex subsidiary. The firm operates through its subsidiaries, including Simafex, Medex, SCI KALB, Guerbet LLC, Guerbet Asie Pacifique and Guerbet GmbH, among others.
Can you provide the latest stock price for GUERBET?
The current stock price of GBT.PA is 15.76 EUR. The price decreased by -1.87% in the last trading session.
Does GUERBET pay dividends?
GUERBET (GBT.PA) has a dividend yield of 2.69%. The yearly dividend amount is currently 0.5.
What is the ChartMill technical and fundamental rating of GBT stock?
GBT.PA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What sector and industry does GUERBET belong to?
GUERBET (GBT.PA) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
Can you provide the growth outlook for GUERBET?
The Revenue of GUERBET (GBT.PA) is expected to decline by -3.65% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the upcoming earnings date for GUERBET?
GUERBET (GBT.PA) will report earnings on 2026-02-04.
GBT.PA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to GBT.PA. When comparing the yearly performance of all stocks, GBT.PA is a bad performer in the overall market: 97.16% of all stocks are doing better.
GBT.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to GBT.PA. The financial health of GBT.PA is average, but there are quite some concerns on its profitability.
GBT.PA Financial Highlights
Over the last trailing twelve months GBT.PA reported a non-GAAP Earnings per Share(EPS) of 0.61. The EPS decreased by -76.89% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 0.96% | ||
| ROA | 0.76% | ||
| ROE | 2.06% | ||
| Debt/Equity | 0.93 |
GBT.PA Forecast & Estimates
10 analysts have analysed GBT.PA and the average price target is 18.61 EUR. This implies a price increase of 18.12% is expected in the next year compared to the current price of 15.76.
For the next year, analysts expect an EPS growth of -70.82% and a revenue growth -3.65% for GBT.PA